Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emoflon vs HyperOil vs Surgery for Chronic Anal Fissure
NCT06617026Phase 2Completed
- Sponsor
- Suez Canal University
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sucralfate, azadirachtin and hyperforin in chronic anal fissure (CAF) (3 arms), sponsored by Suez Canal University. Primary endpoint: REALISE score at 40 days. Started Aug 2024; status: completed.
02
Drugs
sucralfateazadirachtinhyperforin
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on NCT06617026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617026.